Evaluating symptom burden in kidney transplant recipients: validation of the revised Edmonton Symptom Assessment System for kidney transplant recipients - a single-center, cross-sectional study.
Edmonton Symptom Assessment System-revised
kidney transplant recipients
symptom burden
validation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
30
07
2019
revised:
20
09
2019
accepted:
06
01
2020
pubmed:
11
1
2020
medline:
25
6
2021
entrez:
11
1
2020
Statut:
ppublish
Résumé
We assessed the validity of the Edmonton Symptom Assessment System (ESAS-r) in kidney transplant recipients (KTR). A cross-sectional sample of 252 KTR was recruited. Individual ESAS-r symptom scores and symptom domain scores were evaluated. Internal consistency, convergent validity, and construct validity were assessed with Cronbach's α, Spearman's rank correlations, and a priori-defined risk group comparisons. Mean (SD) age was 51 (16), 58% were male, and 58% Caucasian. ESAS-r Physical, Emotional, and Global Symptom Scores demonstrated good internal consistency (α > 0.8 for all). ESAS-r Physical and Global Symptom Scores strongly correlated with PHQ-9 scores (0.72, 95% CI: 0.64-0.78 and 0.74, 95% CI: 0.67-0.80). For a priori-defined risk groups, individual ESAS-r symptom score differed between groups with lower versus higher eGFR [pain: 1 (0-3) vs. 0 (0-2), delta = 0.18; tiredness: 3 (1-5) vs. 1.5 (0-4), delta = 0.21] and lower versus higher hemoglobin [tiredness: 3 (1-6) vs. 2 (0-4), delta = 0.27]. ESAS-r Global and Physical Symptom Scores differed between groups with lower versus higher hemoglobin [13 (6-29) vs. 6.5 (0-18.5), delta = 0.3, and 9 (2-19) vs. 4 (0-13), delta = 0.24] and lower versus higher eGFR [11 (4-20) vs. 6.5 (2-13), delta = 0.21, and 7 (2-16) vs. 3 (0-9), delta = 0.26]. These data support reliability and construct validity of ESAS-r in KTR. Future studies should explore its clinical utility for symptom assessment among KTR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-436Informations de copyright
© 2020 Steunstichting ESOT.
Références
Afshar M, Rebollo-Mesa I, Murphy E, Murtagh FE, Mamode N. Symptom burden and associated factors in renal transplant patients in the U.K. J Pain Symptom Manage 2012; 44: 229.
Brown SA, Tyrer FC, Clarke AL, et al. Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy. Clin Kidney J 2017; 10: 788.
Yong DS, Kwok AO, Wong DM, Suen MH, Chen WT, Tse DM. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med 2009; 23: 111.
Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol 2009; 4: 1057.
Johnson JP, McCauley CR, Copley JB. The quality of life of hemodialysis and transplant patients. Kidney Int 1982; 22: 286.
Almutary H, Bonner A, Douglas C. Symptom burden in chronic kidney disease: a review of recent literature. J Ren Care 2013; 39: 140.
Cukor D, Coplan J, Brown C, et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 484.
El-Majzoub S, Mucsi I, Li M, et al. Psychosocial distress and health service utilization in patients undergoing hemodialysis: a prospective study. Psychosomatics 2019; 60: 385.
Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005; 16: 2487.
Molnar MZ, Ravel V, Streja E, et al. Survival of elderly adults undergoing incident home hemodialysis and kidney transplantation. J Am Geriatr Soc 2016; 64: 2003.
Ozcan H, Yucel A, Avsar UZ, et al. Kidney transplantation is superior to hemodialysis and peritoneal dialysis in terms of cognitive function, anxiety, and depression symptoms in chronic kidney disease. Transplant Proc 2015; 47: 1348.
Czyzewski L, Sanko-Resmer J, Wyzgal J, Kurowski A. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant 2014; 19: 576.
Kaballo MA, Canney M, O'Kelly P, Williams Y, O'Seaghdha CM, Conlon PJ. A comparative analysis of survival of patients on dialysis and after kidney transplantation. Clin Kidney J 2018; 11: 389.
Purnell TS, Auguste P, Crews DC, et al. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. Am J Kidney Dis 2013; 62: 953.
Tennankore KK, Kim SJ, Baer HJ, Chan CT. Survival and hospitalization for intensive home hemodialysis compared with kidney transplantation. J Am Soc Nephrol 2014; 25: 2113.
Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 26: 2988.
Novak M, Molnar MZ, Szeifert L, et al. Depressive symptoms and mortality in patients after kidney transplantation: a prospective prevalent cohort study. Psychosom Med 2010; 72: 527.
Szeifert L, Molnar MZ, Ambrus C, et al. Symptoms of depression in kidney transplant recipients: a cross-sectional study. Am J Kidney Dis 2010; 55: 132.
Bossola M, Di Stasio E, Marzetti E, De Lorenzis K, Pepe G, Vulpio C. Fatigue is associated with high prevalence and severity of physical and emotional symptoms in patients on chronic hemodialysis. Int Urol Nephrol 2018; 50: 1341.
McAdams-DeMarco MA, Ying H, Olorundare I, et al. Individual frailty components and mortality in kidney transplant recipients. Transplantation 2017; 101: 2126.
Molnar-Varga M, Molnar MZ, Szeifert L, et al. Health-related quality of life and clinical outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 58: 444.
Kovacs AZ, Molnar MZ, Szeifert L, et al. Sleep disorders, depressive symptoms and health-related quality of life-a cross-sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrol Dial Transplant 2011; 26: 1058.
Chilcot J, Spencer BW, Maple H, Mamode N. Depression and kidney transplantation. Transplantation 2014; 97: 717.
Bansal A, Tang EE, Khalafi F, et al. Accuracy of Promis-57 depression and anxiety scales compared to legacy instruments among kidney transplant recipients. Transplantation 2018; 102: S311.
Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health 2008; 13: 19.
Yu ZL, Yeoh LY, Seow YY, Luo XC, Griva K. Evaluation of adherence and depression among patients on peritoneal dialysis. Singapore Med J 2012; 53: 474.
Tang E, Ekundayo O, Peipert JD, et al. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients. Qual Life Res 2019; 28: 815.
Weldring T, Smith SMS. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights 2013; 6: 61.
Basch E. Patient-reported outcomes - harnessing patients' voices to improve clinical care. N Engl J Med 2017; 376: 105.
Baumhauer JF. Patient-reported outcomes - are they living up to their potential? N Engl J Med 2017; 377: 6.
Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011; 103: 1808.
Kumnig M, Rumpold G, Hofer S, et al. Patient-reported outcome reference values for patients after kidney transplantation. Wien Klin Wochenschr 2014; 126: 15.
Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res 2012; 21: 1305.
Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 2015; 26: 1846.
Pollak VE, Lorch JA. Effect of electronic patient record use on mortality in End Stage Renal Disease, a model chronic disease: retrospective analysis of 9 years of prospectively collected data. BMC Med Inform Decis Mak 2007; 7: 38.
Gilbert A, Sebag-Montefiore D, Davidson S, Velikova G. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol 2015; 136: 429.
Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review protocol. BMJ Open 2016; 6: e012014.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6.
Watanabe SM, Nekolaichuk CL, Beaumont C. The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology 2012; 21: 977.
Watanabe S, Nekolaichuk C, Beaumont C, Mawani A. The Edmonton Symptom Assessment System-what do patients think? Support Care Cancer 2009; 17: 675.
Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 2011; 41: 456.
Moro C, Brunelli C, Miccinesi G, et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 2006; 14: 30.
Philip J, Smith WB, Craft P, Lickiss N. Concurrent validity of the modified Edmonton symptom assessment system with the Rotterdam symptom checklist and the brief pain inventory. Support Care Cancer 1998; 6: 539.
Baba K, Fransson P, Lindh J. Use of a modified ESAS in cancer patients: a pilot study of patient and staff experiences. Int J Palliat Nurs 2007; 13: 610.
Nekolaichuk C, Watanabe S, Beaumont C. The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991-2006). Palliat Med 2008; 22: 111.
Verberne WR, Das-Gupta Z, Allegretti AS, et al. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the international consortium for health outcomes measurement (ICHOM) CKD working group. Am J Kidney Dis 2019; 73: 372.
van Sandwijk MS, Al Arashi D, van de Hare FM, et al. Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. Nephrol Dial Transplant 2018; 02: 02.
Cancer Care Ontario. Interactive Symptom Assessment and Collection (ISAAC) Tool, 2017, Nov, 7.
Clinical Trials Gov. Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care (EMPATHY),2018.
Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 3189.
Schick-Makaroff K, Tate K, Molzahn A. Use of electronic patient reported outcomes in clinical nephrology practice: a qualitative pilot study. Can J Kidney Health Dis 2019; 6: 2054358119879451.
Wong D, Cao S, Ford H, et al. Exploring the use of tablet computer-based electronic data capture system to assess patient reported measures among patients with chronic kidney disease: a pilot study. BMC Nephrol 2017; 18: 356.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: a comparison of comorbidity indices. Am J Kidney Dis 2005; 46: 136.
Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 2006; 69: 1621.
Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J Pain Symptom Manage 2017; 53: 630.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 3: 329.
Barotfi S, Molnar MZ, Almasi C, et al. Validation of the Kidney Disease Quality of Life-Short Form questionnaire in kidney transplant patients. J Psychosom Res 2006; 60: 495.
Ricardo AC, Hacker E, Lora CM, et al. Validation of the kidney disease quality of life short form 36 (KDQOL-36) US Spanish and English versions in a cohort of hispanics with chronic kidney disease. Ethn Dis 2013; 23: 202.
Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ 1993; 2: 217.
Yang F, Wang VW, Joshi VD, Lau TW, Luo N. Validation of the English version of the Kidney Disease Quality of Life questionnaire (KDQOL-36) in haemodialysis patients in Singapore. Patient 2013; 6: 135.
Chow SK, Tam BM. Is the kidney disease quality of life-36 (KDQOL-36) a valid instrument for Chinese dialysis patients? BMC Nephrol 2014; 15: 199.
Hays RD, Peipert JD, Kallich JD. Problems with analyses and interpretation of data in "use of the KDQOL-36 for assessment of health-related quality of life among dialysis patients in the United States". BMC Nephrol 2019; 20: 447.
Yang F, Wong CKH, Luo N, Piercy J, Moon R, Jackson J. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Eur J Health Econ 2019; 20: 1195.
Shah KK, Murtagh FEM, McGeechan K, et al. Health-related quality of life and well-being in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a cross-sectional study in the UK and Australia. BMJ Open 2019; 9: e027776.
Peipert JD, Nair D, Klicko K, Schatell DR, Hays RD. Kidney disease quality of life 36-item short form survey (KDQOL-36) normative values for the United States dialysis population and new single summary score. J Am Soc Nephrol 2019; 30: 654.
Peipert JD, Bentler P, Klicko K, Hays RD. Negligible impact of differential item functioning between black and white dialysis patients on the kidney disease quality of life 36-item short form survey (KDQOL(TM)-36). Qual Life Res 2018; 27: 2699.
Chong K, Myaskovsky L, Unruh M. A timely evaluation of the psychometric properties of the KDQOL-36. Am J Kidney Dis 2018; 71: 449.
Hall RK, Luciano A, Pieper C, Colon-Emeric CS. Association of kidney disease quality of life (KDQOL-36) with mortality and hospitalization in older adults receiving hemodialysis. BMC Nephrol 2018; 19: 11.
Peipert JD, Bentler PM, Klicko K, Hays RD. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. Am J Kidney Dis 2018; 71: 461.
Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review. PLoS ONE 2017; 12: e0179733.
Yang F, Lau T, Lee E, Vathsala A, Chia KS, Luo N. Comparison of the preference-based EQ-5D and SF-6D health indices in multiethnic Asian patients with end-stage renal disease (ESRD). Value Health 2014; 17: A725.
Galain AI, Alvarez R, Dapueto JJ, Varela A. Prevalence of symptoms and cluster analysis in dialysis patients using Kdqol-36. Value Health 2014; 17: A472.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606.
Glazer K, Rootes-Murdy K, Van Wert M, Mondimore F, Zandi P. The utility of PHQ-9 and CGI-S in measurement-based care for predicting suicidal ideation and behaviors. J Affect Disord 2018. https://doi.org/10.1016/j.jad.2018.05.054
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092.
Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46: 266.
Watnick S, Wang PL, Demadura T, Ganzini L. Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis 2005; 46: 919.
Cukor D, Peterson RA, Cohen SD, Kimmel PL. Depression in end-stage renal disease hemodialysis patients. Nat Clin Pract Nephrol 2006; 2: 678.
Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014; 32: 1605.
Howell D, Keshavarz H, Esplen MJ, et al. Pan-Canadian practice guideline: screening, assessment and management of psychosocial distress, major depression and anxiety in adults with cancer. Canadian Partnership Against Cancer (Cancer Journey Action Group) and the Canadian Association of Psychosocial Oncology, 2010: 1-344.
Lee SY, Chu SH, Oh EG, Huh KH. Low adherence to immunosuppressants is associated with symptom experience among kidney transplant recipients. Transplant Proc 2015; 47: 2707.
Tang E, Ekundayo O, Peipert JD, et al. Validation of the patient-reported outcomes measurement information system (PROMIS)-57 and -29 item short forms among kidney transplant recipients. Qual Life Res 2018; 22: 22.
Gentile S, Beauger D, Speyer E, et al. Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France. Health Qual Life Outcomes 2013; 11: 88.
Cheung PWH, Wong CKH, Samartzis D, et al. Psychometric validation of the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) in Chinese patients with adolescent idiopathic scoliosis. Scoliosis Spinal Disord 2016; 11: 19.
Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS ONE 2012; 7: e31115.
Li B, Cairns JA, Draper H, et al. Estimating health-state utility values in kidney transplant recipients and waiting-list patients using the EQ-5D-5L. Value Health 2017; 20: 976.
Hernández-Alava M, Pudney S, Wailoo A. Quality review of a proposed EQ-5D-5L value set for England. Policy Research Unit in Economic Evaluation of Health & Care Interventions, 2018.
Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ 2011; 2: 53.
Hinkle DE, Wiersma W, Jurs SG. Applied Statistics for the Behavioral Sciences, 5th edn. Boston MA: Houghton Mifflin College Division, 2003.
Khalili-Parapary Y, Heidarzadeh M, Mozaffari N, Naseri P. The psychometric properties and factor structure of Persian version of Edmonton symptom assessment scale in cancer patients. Indian J Palliat Care 2017; 23: 419.
Ganesh V, Zhang L, Chan S, et al. An update in symptom clusters using the Edmonton Symptom Assessment System in a palliative radiotherapy clinic. Support Care Cancer 2017; 25: 3321.
Carvajal A, Centeno C, Watson R, Bruera E. A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer 2011; 47: 1863.
Lt Hu, Bentler P. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling 1999; 6: 1.
Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33.
Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003; 42: 125.
Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747.
Marcen R, Morales JM, Fernandez-Rodriguez A, et al. Long-term graft function changes in kidney transplant recipients. NDT Plus 2010; 3: ii2.
Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G. The relationship between depression and physical symptom burden in advanced cancer. BMJ Support Palliat Care 2015; 5: 381.
Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep 2017; 2: 94.
Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ 2012; 184: E191.
Romano J, Kromrey JD, Coraggio J, Skowronek J, Devine L. Exploring methods for evaluating group differences on the NSSE and other surveys: are the t-test and Cohen’s d indices the most appropriate choices. Annual meeting of the Southern Association for Institutional Research, 2006: 1-51.
Watanabe SM, Nekolaichuk CL, Beaumont C. The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psycho-Oncology 2012; 21: 977.
Cheifetz O, Packham TL, Macdermid JC. Rasch analysis of the Edmonton Symptom Assessment System and research implications. Curr Oncol 2014; 21: e186.
Zimmermann C, Burman D, Bandukwala S, et al. Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. Support Care Cancer 2010; 18: 609.
Cheung WY, Barmala N, Zarinehbaf S, Rodin G, Le LW, Zimmermann C. The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage 2009; 37: 297.
Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000; 88: 2164.
Carvajal A, Hribernik N, Duarte E, Sanz-Rubiales A, Centeno C. The Spanish version of the Edmonton Symptom Assessment System-revised (ESAS-r): first psychometric analysis involving patients with advanced cancer. J Pain Symptom Manage 2013; 45: 129.
Bossola M, Pepe G, Vulpio C. Fatigue in kidney transplant recipients. Clin Transplant 2016; 30: 1387.
Leinau L, Murphy TE, Bradley E, Fried T. Relationship between conditions addressed by hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life. Clin J Am Soc Nephrol 2009; 4: 572.
Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 288: 3027.
Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol 2011; 29: 1029.
Salminen E, Clemens KE, Syrjanen K, Salmenoja H. Needs of developing the skills of palliative care at the oncology ward: an audit of symptoms among 203 consecutive cancer patients in Finland. Support Care Cancer 2008; 16: 3.
Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T, Bruera E. The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med 2006; 9: 296.
Tang E, Dano S, Ayub A, et al. Clinical utility of the Edmonton symptom assessment system to screen for depression and anxiety in kidney transplant recipients. Am J Transplant 2019; 19: 927.
Dano S, Tang E, Chavla G, et al.Measurement characteristics of PROMIS computer adaptive testing (CAT) and ESASr to assess fatigue in kidney transplant recipients. 26th annual scientific conference of the International Society of Quality of Life Research. San Diego, California. 2019; S38-S.
Flythe JE, Hilliard T, Castillo G, et al. Symptom prioritization among adults receiving in-center hemodialysis: a mixed methods study. Clin J Am Soc Nephrol 2018; 13: 735.